# Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF 5993 pMDI Combination in Healthy Volunteers

> **NCT02359292** · PHASE1 · COMPLETED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 50 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** CHF 5993 HS 200/6/25 pMDI
- **DRUG:** CHF 5993 MS 100/6/25 pMDI
- **DRUG:** CHF 5993 HS 200/6/25 pMDI + Charcoal Block
- **DRUG:** CHF 5993 MS 100/6/25 pMDI + Charcoal Block
- **DRUG:** Placebo pMDI

## Key facts

- **NCT ID:** NCT02359292
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2015-04
- **Final completion:** 2015-07
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2021-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02359292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02359292, "Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF 5993 pMDI Combination in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02359292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*